{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:53:03Z","timestamp":1778860383989,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41375-024-02417-1","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:02:01Z","timestamp":1727690521000},"page":"2544-2551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"2417_CR1","doi-asserted-by":"crossref","unstructured":"Liu Y, Su Z, Tavana O, Gu W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 2024;42:946-67.","DOI":"10.1016\/j.ccell.2024.04.009"},{"key":"2417_CR2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","volume":"42","author":"ST Diepstraten","year":"2024","unstructured":"Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, et al. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 2024;42:850\u2013868.e9.","journal-title":"Cancer Cell"},{"key":"2417_CR3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-018-0043-5","volume":"24","author":"A Janic","year":"2018","unstructured":"Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med. 2018;24:947\u201353.","journal-title":"Nat Med"},{"key":"2417_CR4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321\u201337.","journal-title":"Cell"},{"key":"2417_CR5","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson AG, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2417_CR6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"2417_CR7","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1080\/10428194.2021.1957869","volume":"62","author":"SA Patel","year":"2021","unstructured":"Patel SA, Lloyd MR, Cerny J, Shi Q, Simin K, Ediriwickrema A, et al. Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leuk Lymphoma. 2021;62:3348\u201360.","journal-title":"Leuk Lymphoma"},{"key":"2417_CR8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jha2.791","volume":"4","author":"SA Patel","year":"2023","unstructured":"Patel SA, Cerny J, Gerber WK, Ramanathan M, Ediriwickrema A, Tanenbaum B, et al. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions. EJHaem. 2023;4:1059\u201370.","journal-title":"EJHaem"},{"key":"2417_CR9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science"},{"key":"2417_CR10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","volume":"5","author":"AM Hunter","year":"2021","unstructured":"Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5:1017\u201328.","journal-title":"Blood Adv"},{"key":"2417_CR11","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4:5681\u20139.","journal-title":"Blood Adv"},{"key":"2417_CR12","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","volume":"61","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, et al. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leuk Lymphoma. 2020;61:2180\u201390.","journal-title":"Leuk Lymphoma"},{"key":"2417_CR13","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2021006580","volume":"6","author":"SA Patel","year":"2022","unstructured":"Patel SA, Cerny J. TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology. Blood Adv. 2022;6:1917\u20138.","journal-title":"Blood Adv"},{"key":"2417_CR14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2417_CR15","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2417_CR16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41375-024-02157-2","volume":"38","author":"K Nachtkamp","year":"2024","unstructured":"Nachtkamp K, Strupp C, Vukelja M, Kasprzak A, Haase D, Ganster C, et al. The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the D\u00fcsseldorf MDS Registry and proposals for a merged classification. Leukemia. 2024;38:442\u20135.","journal-title":"Leukemia"},{"key":"2417_CR17","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","volume":"39","author":"A Nazha","year":"2021","unstructured":"Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39:3737\u201346.","journal-title":"J Clin Oncol"},{"key":"2417_CR18","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"2417_CR19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536\u201347.","journal-title":"N Engl J Med"},{"key":"2417_CR20","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2021-154151","volume":"138","author":"MT Byrne","year":"2021","unstructured":"Byrne MT, Kurian TJ, Patel DA, Tamari R, Hong S, Abdelhakim H, et al. Non-relapse mortality in TP53-mutated MDS\/AML - a multi-center collaborative study. Blood. 2021;138:2922.","journal-title":"Blood"},{"key":"2417_CR21","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","volume":"131","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, et al. Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations. Blood. 2018;131:2989\u201392.","journal-title":"Blood"},{"key":"2417_CR22","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","volume":"128","author":"J Loke","year":"2022","unstructured":"Loke J, Labopin M, Craddock C, Cornelissen JJ, Labussi\u00e8re-Wallet H, Wagner-Drouet EM, et al. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 2022;128:2922\u201331.","journal-title":"Cancer"},{"key":"2417_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2019-131530","volume":"134","author":"O Chan","year":"2019","unstructured":"Chan O, Hunter A, Talati C, Sallman DA, Asghari H, Song J, et al. Impact of TP53 gene mutation clearance and conditioning intensity on outcome in MDS or AML patients prior to allogeneic stem cell transplantation. Blood. 2019;134:149.","journal-title":"Blood"},{"key":"2417_CR24","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41:4497\u2013510.","journal-title":"J Clin Oncol"},{"key":"2417_CR25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","volume":"37","author":"T Badar","year":"2023","unstructured":"Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, et al. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023;37:799\u2013806.","journal-title":"Leukemia"},{"key":"2417_CR26","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023\u201336.","journal-title":"N Engl J Med"},{"key":"2417_CR27","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","volume":"6","author":"NJ Short","year":"2019","unstructured":"Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019;6:e29\u2013e37.","journal-title":"Lancet Haematol"},{"key":"2417_CR28","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2352-3026(19)30024-9","volume":"6","author":"G Huls","year":"2019","unstructured":"Huls G, Suciu S, Wijermans P, Kicinski M, L\u00fcbbert M. 10-day vs 5-day decitabine: equivalence cannot be concluded. Lancet Haematol. 2019;6:e177.","journal-title":"Lancet Haematol"},{"key":"2417_CR29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2417_CR30","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724\u2013e736.","journal-title":"Lancet Haematol"},{"key":"2417_CR31","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","volume":"127","author":"K Kim","year":"2021","unstructured":"Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127:3772\u201381.","journal-title":"Cancer"},{"key":"2417_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01000-2","volume":"14","author":"T Badar","year":"2024","unstructured":"Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, et al. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024;14:32.","journal-title":"Blood Cancer J"},{"key":"2417_CR33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"2417_CR34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","volume":"37","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Bewersdorf JP, Hasle V, Shallis RM, Thompson E, de Menezes DL, et al. Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia. 2023;37:240\u20133.","journal-title":"Leukemia"},{"key":"2417_CR35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30:666\u201373.","journal-title":"Leukemia"},{"key":"2417_CR36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","volume":"97","author":"CD DiNardo","year":"2022","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97:1035\u201343.","journal-title":"Am J Hematol"},{"key":"2417_CR37","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, et al. Venetoclax combined with FLAG-IDA Induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39:2768\u201378.","journal-title":"J Clin Oncol"},{"key":"2417_CR38","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","volume":"130","author":"E Jabbour","year":"2017","unstructured":"Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN. Blood. 2017;130:1514\u201322.","journal-title":"Blood"},{"key":"2417_CR39","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","volume":"1","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid. 2022;1:EVIDoa2200034.","journal-title":"NEJM Evid"},{"key":"2417_CR40","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11:e15\u2013e26.","journal-title":"Lancet Haematol"},{"key":"2417_CR41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","volume":"402","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:373\u201385.","journal-title":"Lancet"},{"key":"2417_CR42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","volume":"403","author":"U Platzbecker","year":"2024","unstructured":"Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403:249\u201360.","journal-title":"Lancet"},{"key":"2417_CR43","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584\u201394.","journal-title":"J Clin Oncol"},{"key":"2417_CR44","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","volume":"40","author":"A Mishra","year":"2022","unstructured":"Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2022;40:3985\u201393.","journal-title":"J Clin Oncol"},{"key":"2417_CR45","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","volume":"10","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023;10:e272\u2013e283.","journal-title":"Lancet Haematol"},{"key":"2417_CR46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286\u201399.","journal-title":"Cell"},{"key":"2417_CR47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271\u201385.","journal-title":"Cell"},{"key":"2417_CR48","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41:2815\u201326.","journal-title":"J Clin Oncol"},{"key":"2417_CR49","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results. J Clin Oncol. 2023;41:4893\u2013904.","journal-title":"J Clin Oncol"},{"key":"2417_CR50","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","volume":"136","author":"Sallman","year":"2020","unstructured":"Sallman, McLemore DA, Aldrich AL AF, Komrokji RS, McGraw KL, Dhawan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136:2812\u201323.","journal-title":"Blood"},{"key":"2417_CR51","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","volume":"99","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024;99:E32\u2013E36.","journal-title":"Am J Hematol"},{"key":"2417_CR52","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024;11:e38\u2013e50.","journal-title":"Lancet Haematol"},{"key":"2417_CR53","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141:1265\u201376.","journal-title":"Blood"},{"key":"2417_CR54","first-page":"4147","volume":"6","author":"MY Konopleva","year":"2022","unstructured":"Konopleva MY, R\u00f6llig C, Cavenagh J, Deeren D, Girshova L, Krauter J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6:4147\u201356.","journal-title":"Blood Adv"},{"key":"2417_CR55","volume":"13","author":"BZ Carter","year":"2023","unstructured":"Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13:57.","journal-title":"Blood Cancer J"},{"key":"2417_CR56","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.2022019047","volume":"142","author":"BZ Carter","year":"2023","unstructured":"Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, et al. Epichaperome inhibition targets TP53-mutant AML and AML stem\/progenitor cells. Blood. 2023;142:1056\u201370.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02417-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02417-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:04:09Z","timestamp":1732532649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02417-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2417"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02417-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SAP served on the Myelodysplastic Syndromes advisory board and the Acute Myeloid Leukemia advisory board for Bristol Myers Squibb, the Acute Leukemia advisory board for Syndax, and the Multiple Myeloma advisory board for Pfizer. SAP received travel support from AAMDSIF in 2024.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}